Colorectal Surgery Wiki

Rectal Cancer

Properties1
tagscolorectal, rectal-cancer, tme, staging

12 min read

Rectal Cancer

The wiki’s rectal cancer content is organized around two complementary sources: the treatment- focused Total Neoadjuvant Therapy (TNT) concept page (from a primary-literature-synthesizing review) and this page’s staging/surgical/survival content (from a textbook reference chapter, Sabiston Ch52 - Rectal Cancer Surgery — not primary literature, treat accordingly).

Anatomy

The rectum is the distal portion of the large intestine, divided into three parts: proximal rectum (~15–10 cm from the anal verge), mid rectum (10–5 cm from the anal verge), and distal rectum (5 cm and less). The upper mid rectum and the distal rectum are extraperitoneal. The rectum sits in the narrow pelvis with close anatomic relations to the genitourinary organs (bladder, seminal vesicles, prostate, vagina, uterus) and the pelvic autonomic nerves. It’s an important fecal reservoir and plays an active role in defecation, continuous with the sphincter apparatus; its distal mucosa is fundamental to discriminating between stool and gas.

Because of the boney confines of the pelvis, obtaining a clear circumferential margin is harder than for colon cancer within the peritoneal cavity — a key reason rectal cancer carries a higher local recurrence risk and a more involved preoperative workup than colon cancer. Based on blood supply, the lower half of the rectum drains into the systemic circulation and can therefore metastasize through that route to the lungs, whereas upper rectal cancers metastasize to the liver, just as colon cancers do.

Preoperative evaluation

~44,000 new rectal cancer diagnoses per year in the US, with an increasing trend of young patients being diagnosed — a demographic shift projected to continue over the next 10–15 years.

Physical exam: assess whether the tumor is within reach of the examining finger; if palpable, sphincter tone can be assessed — a major factor (in most patients) in whether a sphincter-sparing approach is feasible. Document pathology location as anterior/posterior/left/right (avoid “o’clock” notation, which is ambiguous depending on patient position). In women, always document whether there is invasion of the rectovaginal septum — a prime consideration for whether a vaginal resection will be needed. Sphincter involvement assessment is critical. A proctoscopic exam assessing tumor height should be performed if possible — height assessments with flexible endoscopy are notoriously inaccurate (what’s judged 15 cm on flexible exam can be meaningfully closer or farther on rigid endoscopy). A tilt table in knee-chest position can be particularly useful in extremely obese patients to permit a good exam.

Staging

Staged like colon cancer with the TNM system (see Colorectal Cancer Staging (TNM) for the general framework), but accurate preoperative assessment of local spread matters more for rectal cancer, since it determines the need for preoperative neoadjuvant therapy (see Total Neoadjuvant Therapy (TNT) for the risk-stratified indications).

  • Endorectal ultrasound (ERUS) — performed by a surgeon, gastroenterologist, or radiologist. Much less expensive than MRI, can be done without sedation, and provides accurate T-stage assessment. Not all facilities have ERUS capability. Lymph node detection accuracy is meaningfully lower than T-stage detection accuracy in most studies.
  • MRI — performed by a radiologist, per a specific rectal cancer protocol (accessed in the same axis as the rectum; helpful to fill the rectum with ultrasound gel mixed with gadolinium). Interpretation is dependent on the radiologist’s experience. Pelvic MRI permits assessment of lymph node involvement, circumferential resection margin status, and extrarectal disease — none of which is possible with ERUS.

Clinically T3 and node-positive rectal cancers, and cancers close to the sphincter where sphincter sparing is desired, are generally recommended for preoperative neoadjuvant chemoradiation.

Evolution of treatment: downstaging, TME, and the circumferential margin

There has been a major evolution in rectal cancer treatment with the recognition that neoadjuvant therapy can “downstage” tumors — facilitating surgery, increasing the chance of a sphincter-sparing operation, and improving functional results, compared with the same treatment given after surgery.

  • The German Rectal Cancer Study (results published 2004) randomized T3/T4 rectal cancer patients to preoperative vs. postoperative chemoradiation. No overall difference in morbidity or mortality, but lower rates of local recurrence and both acute and long-term toxicity with preoperative treatment — and significantly more patients in the preoperative group were able to undergo a sphincter-sparing procedure.
  • Richard Heald popularized total mesorectal excision (TME) in the 1980s — complete excision of the mesorectum intact using sharp dissection — associated with a much lower local recurrence rate and improved survival.
  • Quirke and colleagues emphasized the role of the circumferential resection margin (CRM) in reducing recurrence. The combination of preoperative chemoradiation plus TME plus recognition of the CRM’s importance has driven the improved outcomes seen in modern rectal cancer surgery.
  • Professor Habr-Gama led development of a “watch and wait” strategy built on the concept of complete pathologic response to neoadjuvant therapy. Initially reported in a small group of patients undergoing preoperative neoadjuvant therapy, 27% had no clinically detectable evidence of cancer after treatment. Among rectal cancer patients undergoing neoadjuvant chemoradiation overall, approximately 20% achieve a “complete response.” A restaging is typically performed after treatment; in high-risk patients, or after an in-depth discussion, a watch-and-wait strategy may be chosen for select patients — this is not currently standard of care. Absence of luminal disease does not imply absence of disease overall, and these patients must be followed longitudinally with physical, endoscopic, and cross-sectional (preferably MRI) exams.
  • Tumor regression grading: several staging systems have been proposed to grade the degree of tumor regression after neoadjuvant therapy; one common scale runs 1–3, with 1 = complete response and 3 = minimal response. Any AJCC stage with a “y” prefix (ypTNM) reflects staging obtained after neoadjuvant treatment.

Neoadjuvant trial evidence: TNT and radiation-omission

Full trial-by-trial detail lives on Total Neoadjuvant Therapy (TNT); this section summarizes the treatment-selection implications for this page.

Six primary-literature RCTs (five with results, one protocol-only) now back the wiki’s neoadjuvant treatment content (previously only a secondary review and the textbook chapter above):

  • Higher-risk LARC (cT4, N2, MRF+, or EMVI+): Bahadoer 2021 - RAPIDO Trial (SCRT + chemo) and Conroy 2024 - PRODIGE 23 Long-Term Results (chemotherapy-first) both show TNT reduces distant metastases substantially vs standard CRT. Only PRODIGE 23 shows a mature overall-survival benefit (7-year OS 81.9% vs 76.1%); RAPIDO showed no OS benefit at 3 years or at 5.6 years (Dijkstra 2023 - RAPIDO 5-Year Locoregional Failure), and at that longer follow-up its numerically-worse-at-3y locoregional recurrence rate became statistically significant (10.2% vs 6.1%, P=0.027). That local-control trade-off is not replicated in Jin 2022 - STELLAR Trial (also SCRT-based TNT, numerically better local control than CRT) or in Ciseł 2019 - POLISH II Long-Term Results (SCRT + consolidation FOLFOX4 in a higher-risk cT4/fixed-cT3 population, no difference in local control, distant metastases, or OS in either direction at 8 years). This cross-trial disagreement — a confirmed RAPIDO-specific finding, not a TNT class effect — is detailed in Total Neoadjuvant Therapy (TNT)‘s Efficacy section, with the full four-trial comparison table.
  • Lower-risk, sphincter-sparing-eligible LARC (cT2N+, cT3N0, or cT3N+ without high-risk features): Schrag 2023 - PROSPECT Trial found neoadjuvant FOLFOX with selective (not routine) chemoradiotherapy noninferior to routine CRT for DFS, letting ~90% of patients avoid pelvic radiation entirely with local recurrence remaining under 2% in both arms. This is a distinct clinical question from TNT (radiation omission for good responders in lower-risk disease, vs. treatment intensification/resequencing for higher-risk disease) and the two shouldn’t be conflated when selecting neoadjuvant strategy. Brouquet 2020 - GRECCAR16 Trial Protocol tests a related but distinct radiation-omission question (FOLFIRINOX entirely replacing CRT in CRM-negative resectable LARC) — protocol only, no results yet.

Net effect on treatment selection: the risk-stratified indications already described in Total Neoadjuvant Therapy (TNT)‘s Indications table are now grounded in primary trial data for the higher-risk end (four trials, including POLISH II), and PROSPECT adds primary-literature support for a radiation-sparing approach at the lower-risk end. Remaining un-ingested: the IDEA duration collaboration (see adjuvant-chemotherapy section below) and results (not yet published) for JANUS and NORAD01-GRECCAR16, both now tracked via their protocol papers (Alvarez 2024 - JANUS Trial Protocol, Brouquet 2020 - GRECCAR16 Trial Protocol).

Survival, surveillance, and adjuvant chemotherapy

5-year survival by stage: stage I ~90%; stage II ~75%; stage III (positive lymph nodes) ~50%; distant, nonresectable metastases ~5%. Patients with resectable liver metastases amenable to curative resection with free margins and favorable clinical risk factors may have a 5-year survival up to 60%. Most recurrences occur within the first 2 years after resection of the primary tumor — close follow-up in this interval matters for early detection of recurrence or a metachronous tumor amenable to curative treatment (the chapter refers readers to the ASCRS Practice Guideline for Surveillance After Curative Treatment of Colon and Rectal Cancer for full detail).

Follow-up: office visits with CEA levels every 6 months for 5 years after surgery, then annually. Rising CEA requires additional tests to identify recurrent/metastatic disease. Colonoscopy scheduled 1 year after surgery (or 3–6 months after surgery if the entire colon wasn’t fully investigated at diagnosis); repeat colonoscopy every 3 years if no adenomas found, every year if adenomatous polyps are found, until the colon is clean. Chest and abdominal CT performed annually.

Adjuvant chemotherapy (indications by postoperative pathologic stage):

  • Stage I (tumor invades muscularis propria, negative nodes): follow-up alone is appropriate — no chemotherapy.

  • Stage II (tumor penetrates pericolic fat, negative nodes): in the absence of risk factors, limited evidence of benefit from adjuvant chemotherapy — absolute survival advantage with 5-FU/leucovorin about 3–4% (borderline significant per the cited meta-analysis). A recent meta-analysis (Bockelman et al.) found 5-year DFS with vs. without chemotherapy of 81.4% vs. 79.3% respectively. Relative indications for chemotherapy in stage II can include: poorly differentiated cancer (G3–4), vascular/perineural invasion, obstruction, perforation, adjacent organ invasion (pT4), or an inadequate number of examined lymph nodes (<12). Even in these higher-risk patients, no definitive value for adjuvant chemotherapy has been demonstrated, and adding oxaliplatin does not add benefit. No difference in 10-year overall survival has been observed between low- and high-risk stage II categories, and no advantage has been derived from an oxaliplatin-based regimen. MSI is another relevant characteristic here — MSI-H is more frequent in stage II disease (22%) than in stages III (12%) or IV (3%) and appears to have a favorable prognostic significance in stage II specifically. Adjuvant 5-FU treatment seems to have a detrimental effect on survival in MSI-H stage II patients specifically, but not stage III — all this is described as uncertain-effectiveness territory.

  • Stage III (positive lymph nodes): adjuvant chemotherapy is indicated. 5-FU and leucovorin combined with oxaliplatin in the FOLFOX protocol; the CAPOX (Xelox) regimen substitutes oral capecitabine for infusional 5-FU/leucovorin. A pooled analysis of six international phase III duration trials (the IDEA collaboration) evaluated 3 vs. 6 months of adjuvant FOLFOX/CAPOX; overall, 3 months was not confirmed noninferior to 6 months for 3-year DFS, but a risk-class interaction emerged (not pre-planned before the study): low-risk patients defined as pT3pN1, high-risk as pT4 (any N) or N2. In low-risk patients, 3 months (4 cycles) of CAPOX was noninferior to 6 months of the same regimen (3-year DFS 85.0% vs. 83.1%). In high-risk patients, 3 months of CAPOX was also sufficient (64.1% vs. 64.0%). For FOLFOX specifically, 6 months appeared superior to 3 months regardless of risk group (61.5% vs. 64.7% in high-risk). Caveat: patients were not randomized to receive CAPOX vs. FOLFOX, so this comparison between regimens is not a controlled comparison.

  • Metastatic disease: the regimen framework below covers systemic (hepatic/pulmonary) spread. Peritoneal metastases are a distinct clinical scenario with their own primary-literature evidence base — see Cytoreductive Surgery and HIPEC (PRODIGE 7 found no OS/RFS benefit from adding HIPEC to cytoreductive surgery for colorectal peritoneal metastases, plus significantly more 60-day morbidity with HIPEC added).

    Treatment selection weighs tumor burden, treatment goal (chronicity), induction of resectability in borderline-resectable disease, primary tumor site/age/ comorbidities, patient preference, and molecular biology (N-RAS, K-RAS, BRAF mutation status). Regimen framework:

    1. Anti-EGFR antibodies (panitumumab, cetuximab) can be used in pan-RAS wild-type and BRAF wild-type disease. Mutational analysis can be performed on the primary tumor but is preferably also done on the metastatic tumor.
    2. Standard treatment in BRAF-mutated metastatic disease: FOLFOXIRI (oxaliplatin + irinotecan + 5-FU/leucovorin) plus bevacizumab — BRAF-mutated patients have the worst prognosis of this group.
    3. For right-sided primary tumors, adding anti-EGFR antibodies to chemotherapy is not superior to chemotherapy alone as first-line treatment, so anti-EGFR agents are usually not given in this setting; doublets (FOLFOX/FOLFIRI) or the triplet FOLFOXIRI in fit patients, combined with bevacizumab, may be the best choice.
    4. For left-sided primary tumors, adding cetuximab or panitumumab to FOLFOX/FOLFIRI could be first-line; FOLFOXIRI can also be considered.
    5. In older or unfit patients unable to tolerate doublets, capecitabine with bevacizumab is an appropriate option. If the treatment goal is resection of hepatic metastases, no more than six cycles of chemotherapy should be given beforehand to avoid hepatic toxicity (steatohepatitis with irinotecan, sinusoidal damage with oxaliplatin); bevacizumab must be stopped 6 weeks before hepatic resection due to its detrimental effect on wound healing, and can be restarted 4 weeks after surgery or once wounds have healed.

Open items / gaps

  • MRF (mesorectal fascia) involvement and EMVI (extramural vascular invasion), referenced in Total Neoadjuvant Therapy (TNT)‘s indications, still aren’t independently defined with their own detail — this chunk didn’t cover them explicitly.
  • Primary trial data now ingested for RAPIDO (including its 5-year locoregional-recurrence follow-up), PRODIGE 23, STELLAR, and POLISH II (see “Neoadjuvant trial evidence” section above) and for the radiation-omission PROSPECT trial. GRECCAR16 and JANUS protocols are also ingested but have no results yet. The IDEA duration collaboration is still not independently ingested — only available via this page’s own adjuvant-chemotherapy section above (sourced from the Sabiston textbook chapter).
  • MMRd/MSI testing’s role beyond the stage-II prognostic question above not covered in depth.
  • Watch-and-wait protocol specifics (surveillance interval, salvage surgery triggers) not detailed beyond “not currently standard of care.”

Graph View

Backlinks